Patient-reported outcomes and quality of life in ALTA: The randomized phase 2 study of brigatinib (BRG) in advanced ALK+ non–small cell lung cancer (NSCLC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback